Deutsche Biotech Innovativ AG
Deutsche Biotech Innovativ AG invests funds from capital increase in clinical development of sepsis drug Adrecizumab
DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Capital Increase PRESS RELEASE Deutsche Biotech Innovativ AG invests funds from capital increase in clinical development of sepsis drug Adrecizumab Both members of DBI AG’s Management Board, Dr Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialized in blood biomarkers. It was sold in 2009 for around 330 million euro. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie). For more information, please contact: Deutsche Biotech Innovativ AG Kirchhoff Consult AG 2015-11-25 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
416159 2015-11-25 |